Journal article
Mammographic density: A potential monitoring biomarker for adjuvant and preventative breast cancer endocrine therapies
MS Shawky, H Martin, HJ Hugo, T Lloyd, KL Britt, A Redfern, EEW Thompson
Oncotarget | IMPACT JOURNALS LLC | Published : 2017
Abstract
Increased mammographic density (MD) has been shown beyond doubt to be a marker for increased breast cancer risk, though the underpinning pathobiology is yet to be fully elucidated. Estrogenic activity exerts a strong influence over MD, which consequently has been observed to change predictably in response to tamoxifen anti-estrogen therapy, although results for other selective estrogen receptor modulators and aromatase inhibitors are less consistent. In both primary and secondary prevention settings, tamoxifen-associated MD changes correlate with successful modulation of risk or outcome, particularly among pre-menopausal women; an observation that supports the potential use of MD change as a..
View full abstractGrants
Awarded by NBCF through a National Collaborative Research Network award
Funding Acknowledgements
M.S.S would like to thank the Ministry of Higher Education-Missions sector, Egypt and the British Council for their support through Newton-Musharafa programme via the Egyptian Cultural Bureau in London. This work was supported in part by the Victorian Breast Cancer Research Consortium, the St. Vincent's Hospital (Melbourne) Research Endowment Fund, the National Breast Cancer Foundation and the University of Melbourne Research Grant Support Scheme (MRGSS), the Translational Research Institute (TRI SPORE grant), and the Princess Alexander Hospital Foundation (ALS Breast Cancer Grant), Australia. KB was supported by an NBCF Early Career Fellowship. AR was supported by Clinical Research Fellowship from Cancer Council WA. EWT was supported in part by the NBCF through a National Collaborative Research Network award (CG-10-04).